These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19912594)

  • 1. What's in a perspective?
    Glick HA
    Value Health; 2010; 13(1):2. PubMed ID: 19912594
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacoeconomics--survey and status].
    Pedersen KM
    Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical research: cost savings through innovation.
    Cohen KR; Levy RA
    AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463
    [No Abstract]   [Full Text] [Related]  

  • 4. [Discount for only one drug of the same group leads to impaired health care quality].
    Bergström R
    Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
    [No Abstract]   [Full Text] [Related]  

  • 5. Generic versus brand name drugs in psychopharmacology: a pharmacoeconomic perspective.
    Emanuele E
    South Med J; 2011 Oct; 104(10):715-6. PubMed ID: 21941163
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicine and the pharmaceutical industry: what's right, what's wrong, and what's to come.
    Tan SY
    Singapore Med J; 1998 Mar; 39(3):91-5. PubMed ID: 9632964
    [No Abstract]   [Full Text] [Related]  

  • 7. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V.
    Mycka JM; Dellamano R; Kolassa EM; Wonder M; Ghosh S; Hay JW; Smeeding J
    Value Health; 2010; 13(1):25-7. PubMed ID: 19883402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?
    Alifrangis C; Krell J; Stebbing J
    Eur J Cancer; 2011 Jun; 47(9):1285-6. PubMed ID: 21550231
    [No Abstract]   [Full Text] [Related]  

  • 9. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
    Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
    Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of pharmaceutical companies: what's at stake for America. Executive summary from a report prepared by the Boston Consulting Group.
    Broshy E
    Ann N Y Acad Sci; 1994 Nov; 729():111-26; discussion 139-42. PubMed ID: 7998722
    [No Abstract]   [Full Text] [Related]  

  • 11. [Guidelines of the Pharmaceutical Benefits Board for health economics evaluations. Cost-efficiency analysis from a national perspective].
    Lundin D; Carlsson P; Levin LA; Persson U
    Lakartidningen; 2006 Nov 22-28; 103(47):3716-8. PubMed ID: 17212321
    [No Abstract]   [Full Text] [Related]  

  • 12. Measure for measure.
    Dughan L
    Biotechnology (N Y); 1995 Sep; 13(9):949-53. PubMed ID: 9678952
    [No Abstract]   [Full Text] [Related]  

  • 13. [Commercialization of results of intellectual activities in pharmaceutical industry].
    Posylkina OV; Timaniuk VN; Gladukh EV
    Lik Sprava; 2002; (8):16-9. PubMed ID: 12669531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
    Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
    Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
    Zaric GS; O'brien BJ
    Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomics comes of age?
    Walley T; Breckenridge A
    Clin Pharmacol Ther; 2008 Aug; 84(2):279-80. PubMed ID: 18563057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germany: putting economics before ethics.
    Lancet; 2010 Jul; 376(9736):142. PubMed ID: 20638552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.